Drug Profile

PRTH 101

Alternative Names: PRTH-101

Latest Information Update: 16 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Parthenon Therapeutics
Developer Incendia Therapeutics
Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
Mechanism of Action Discoidin domain receptor 1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Phase I Solid tumours

Most Recent Events

03 Dec 2024 Incendia Therapeutics plans a phase II trial for Solid tumours in the second half of 2025.
10 Sep 2024 Incendia Therapeutics plans phase-II/III trial for Solid tumours
13 Nov 2023 Incendia Therapeutics plans a phase II clinical trial in Solid tumors

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com